An enzyme that plays a crucial role in the citric acid cycle (Krebs cycle), which is essential for cellular metabolism. Mutations in the IDH1 gene have been implicated in various types of cancer, particularly gliomas and acute myeloid leukemia (AML).
Expression in Cancers: IDH1 is expressed in various tissues, and its expression can be altered in cancer. Mutations in the IDH1 gene, particularly the R132H mutation, are commonly found in certain types of tumors, including gliomas and secondary glioblastomas, as well as in a subset of acute myeloid leukemia cases.
Prognostic Implications: The presence of IDH1 mutations is associated with distinct clinical outcomes. In gliomas, IDH1 mutations are generally linked to a better prognosis compared to wild-type IDH1. Patients with IDH1-mutant gliomas often have longer survival rates and respond differently to treatment. In AML, IDH1 mutations can also influence prognosis, with some studies suggesting that they may be associated with a favorable response to certain therapies.
Oncogenic Potential: Mutant IDH1 is considered an oncogene due to its role in altering cellular metabolism. The R132H mutation leads to a neomorphic enzyme activity that converts alpha-ketoglutarate to 2-hydroxyglutarate (2-HG), an oncometabolite that can inhibit various α-ketoglutarate-dependent dioxygenases, including those involved in DNA and histone demethylation. This alteration in metabolism and epigenetic regulation contributes to tumorigenesis and the development of cancer.
IDH1 (Isocitrate Dehydrogenase 1) is not classified as a traditional oncogene. Instead, it is considered a mutated metabolic enzyme that can contribute to oncogenesis when mutated. Here’s a more detailed explanation:
(Will delete Record if Target field = "Delete") Home